Table 3.
Clinical parameters before and after 12-weeks’ treatment with Nigella sativa or placebo
| Nigella sativa | Control | Differences between groups | |||||
|---|---|---|---|---|---|---|---|
| Baseline | After 12 weeks | Mean change | Baseline | After 12 weeks | Mean change | ||
| BMI | 26.31 (4.89) | 25.78 (4.73) | -0.53 * (1.10) | 26.03 (4.66) | 26.29 (4.87) | -0.28 (1.12) | NS |
| Waist/Hip ratio | 0.82 (0.06) | 0.80 (0.06) | -0.02 (0.05) | 0.87 (0.06) | 0.81 (0.06) | -0.006 (0.05) | NS |
| FBS | 5.64 (1.64) | 5.55 (0.87) | -0.09 (1.35) | 5.65 (1.55) | 5.61 (1.32) | -0.02 (1.78) | NS |
| Total cholesterol | 5.82 (1.22) | 5.56 (1.17) | -0.25 * (0.61) | 5.84 (1.19) | 5.76 (1.26) | 0.08 (0.58) | NS |
| HDL | 1.56 (0.38) | 1.73 (0.47) | 0.17 * (0.33) | 1.52 (0.45) | 1.58 (0.42) | 0.08 (0.28) | NS |
| LDL | 4.29 (5.28) | 3.35 (1.09) | -0.93 (4.98) | 4.30)5.12) | 3.39 (1.25) | -0.91 (4.95) | P=0.02 |
| TG | 1.42 (0.84) | 1.37 (0.75) | -0.05 (0.64) | 1.41 (0.79) | 1.45 (0.72) | 0.04 (0.59) | NS |
| Creatinine | 67.31 (24.87) | 77.29 (27.87) | 9.98 * (10.53) | 65.76 (25.32) | 69.72 (20.89) | 4.96 (17.22) | NS |
| Total billirobine | 12.80 (5.97) | 11.27 (4.41) | -1.52* (3.41) | 12.74 (5.36) | 12.68 (5.97) | -0.61 (3.31) | NS |
| B/P systolic | 122.32 (15.25) | 117.63 (14.65) | -4.69 * (11.15) | 121.42 (14.89) | 118.18 (15.40) | 3.23 * (12.16) | NS |
| B/P diastolic | 79.07 (7.76) | 73.96 (9.48) | -5.10 * (6.96) | 78.42 (8.48) | 74.50 (9.30) | -3.90 * (8.61) | NS |
Data are presented as the Mean values (SD)
NS: not significant
* P<0.05 (paired t-test for the evolution within the treatment group)